BAY 1214784

BAY 1214784 is a potent, selective, and orally active antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R) . BAY 1214784 is a spiroindoline derivative compound. BAY 1214784 effectively lowers plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability. BAY 1214784 has the potential for the research of uterine fibroids[1].

Product Specifications

CAS Number

[1631164-25-4]

UNSPSC

12352005

Target

GnRH Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bay-1214784.html

Purity

99.8

Solubility

DMSO : 42 mg/mL (ultrasonic; warming)

Smiles

O=S(N1[C@@](C2CC2)([H])C3(CCS(=O)(CC3)=O)C4=CC(C(NCC5=C(C=C(C=N5)C(F)(F)F)Cl)=O)=CC=C41)(C6=CC=C(C=C6)F)=O

Molecular Formula

C29H26ClF4N3O5S2

Molecular Weight

672.11

References & Citations

[1]Panknin O, et al. Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women. J Med Chem. 2020;63 (20) :11854-11881